Abstracts Archive - Page 208 of 2425 - ACR Meeting Abstracts

Abstract Number: 0650 • ACR Convergence 2023
Understanding the Employment Landscape in People with Systemic Sclerosis
Hila Jazayeri¹, Zareen Ahmad¹, Monique Gignac² and Sindhu Johnson³, ¹University of Toronto, Toronto, ON, Canada, ²Institute for Work & Health, Toronto, ON, Canada, ³Division of Rheumatology, Department of Medicine, Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western and Mount Sinai Hospitals; Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada
Background/Purpose: Systemic sclerosis (SSc) is a systemic rheumatic disease that restricts participation in various life roles, including in the workplace. Our objectives were to identify…
Abstract Number: 0617 • ACR Convergence 2023
Pulmonary Rehabilitation in Connective Tissue Disease-Related Interstitial Lung Diseases
Rosemary Gedert¹, Suiyuan Huang², Maya Sabbagh², Melissa McInroy², Steven Huang², Dinesh Khanna² and Vivek Nagaraja³, ¹University of Michigan, Onsted, MI, ²University of Michigan, Ann Arbor, MI, ³Mayo Clinic Arizona, Scottsdale, AZ
Background/Purpose: Interstitial lung disease (ILD) is a common manifestation of connective tissue disease (CTD)1. Pulmonary rehabilitation (PR) can be utilized to improve dyspnea and quality…
Abstract Number: 0651 • ACR Convergence 2023
Abnormal Nailfold Video-capillaroscopy Is Independently Associated with non-UIP Radiographic Patterns in Autoimmune ILD: A Multicenter Study from the NEREA Registry
Jesus Loarce-Martos¹, Hilda Godoy², Laura Cebrian³, M Jesus Rodriguez-Nieto⁴, Juan Rigual⁵, Rosalía Laporta², Belen Lopez-Muñiz³, lydia Abasolo⁶, Olga Sanchez Pernaute⁷ and Fredeswinda Romero⁷, ¹Ramón y Cajal University Hospital, Madrid, Spain, ²Hospital Universitario Puerta de Hierro, Madrid, Spain, ³Hospital Universitario Infanta Leonor, Madrid, Spain, ⁴Pulmonology department, Hospital Fundación Jimenez Díaz, Madrid, Spain, ⁵Pulmonology department, Hospital Ramón y Cajal,, Madrid, Spain, ⁶Hospital Clínico San Carlos, Madrid, Spain, ⁷IIS-HU Fundación Jiménez Díaz, Madrid, Spain
Background/Purpose: The aim of this study is to describe the nailfold video-capillaroscopy (NVC) findings in patients with interstitial lung disease associated to connective tissue diseases…
Abstract Number: 0590 • ACR Convergence 2023
Comparing Safety and Efficacy of Sodium-Glucose Co-Transporter 2 Inhibitors versus Dipeptidyl Peptidase 4 Inhibitors in Patients with Systemic Lupus Erythematosus and Comorbid Type 2 Diabetes Mellitus
Jui-En Lo¹, Pin-Chia Huang², George Tsokos³, Vasileios Kyttaris⁴, Karen Costenbader⁵ and Kevin Sheng-Kai Ma², ¹Center for Global Health, Perelman School of Medicine, Philadelphia, PA, ²Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, ³Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, ⁴BIDMC, Boston, MA, ⁵Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Sodium-glucose co-transporter 2 inhibitors (SGLT2i), originally approved as oral hypoglycemic agents for type 2 diabetes (T2D), have been shown to reduce progression to end-stage…
Abstract Number: 0592 • ACR Convergence 2023
Real-World Treatment Patterns in Patients with Systemic Lupus Erythematosus: An Analysis of the SLE Prospective Observational Cohort Study (SPOCS)
Martin Aringer¹, Laurent Arnaud², Richard A. Furie³, Eric Morand⁴, Christine Peschken⁵, Barnabas Desta⁶, Eleni Rapsomaniki⁷, Jonatan Hedberg⁸, Tina Grünfeld Eén⁸, Alessandro Sorrentino⁹, Canna Ghia⁹, Stephanie Chen¹⁰ and Bo Ding⁸, ¹Faculty of Medicine TU Dresden, Dresden, Germany, ²University Hospitals of Strasbourg, Strasbourg, France, ³Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, ⁴Monash University, Centre for Inflammatory Diseases, Melbourne, Australia, ⁵University of Manitoba, Winnipeg, MB, Canada, ⁶BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, ⁷BioPharmaceuticals Medical, AstraZeneca, Cambridge, United Kingdom, ⁸BioPharmaceuticals Medical, AstraZeneca, Gothenburg, Sweden, ⁹Medical Affairs, AstraZeneca, Cambridge, United Kingdom, ¹⁰BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, MD
Background/Purpose: The international SLE Prospective Observational Cohort Study (SPOCS) collected data on patients with moderate to severe SLE disease activity from June 2017 through November…
Abstract Number: 0535 • ACR Convergence 2023
Pharmacologic Treatment of Ankylosing Spondylitis in a Large Urban Medical Center: Effects of Socioeconomic Status, Race/Ethnicity and Sex
EA TROY¹, ZT Chan¹, WL GALLANTER², EM Adams³, Mina Al-Awqati² and Huan Chang¹, ¹University of Illinois at Chicago; Jesse Brown VA Medical Center, Chicago, IL, ²University of Illinois at Chicago, Chicago, IL, ³Jesse Brown VA Medical Center, Chicago, IL
Background/Purpose: Ankylosing spondylitis (AS) is estimated to affect up to 1,647,500 Americans, resulting in significant disability and lost productivity for affected individuals. Biologic medications reduce…
Abstract Number: 0423 • ACR Convergence 2023
Detection of Citrullinated Proteins Recognized by a Novel Chimeric Antigen Receptor TregTherapy in Both Synovial Fluid and Serum from Patients with Rheumatoid Arthritis
Sara Charmsaz¹, Jeff Tracy¹, Elizabeth Whalen¹, John Bui¹, Anne-Renee van der Vuurst de Vries¹, Vivianne Malmström² and Michelle Blake¹, ¹Sonoma Biotherapeutics, Seattle, WA, ²Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Rheumatoid arthritis (RA) is one of the most common autoimmune diseases and despite many therapeutic options, an unmet medical need persists for novel therapies…
Abstract Number: 0599 • ACR Convergence 2023
Targeted Inhibition of Cathepsins Limits the Intracellular Complement Activation in Lupus Nephritis Podocytes
Ana Kunzler¹, Meenakshi Jha¹, Masataka Umeda², Rhea Bhargava², Maria Tsokos¹, George Tsokos² and Abhigyan Satyam², ¹Beth Israel Deaconess Medical Center, Boston, MA, ²Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
Background/Purpose: Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease that leads to damage to several tissues and organs. Inflammation of the kidney is one…
Abstract Number: 0616 • ACR Convergence 2023
Does Systemic Sclerosis Affect the Interpretation of Mammograms? A Retrospective Cohort Study
Lea Meir¹, Tegveer Sandhu², Weiwei Chi² and Gabriela Santiago², ¹Icahn School of Medicine, New York, NY, ²Icahn School of Medicine at Mount Sinai, New York, NY
Background/Purpose: Systemic Sclerosis is an autoimmune disorder marked by thickened and hardened skin. Cutaneous cutis, the deposition of insoluble calcium salts in the skin and…
Abstract Number: 0646 • ACR Convergence 2023
Racial Variability in Immune Responses Only Partially Explains Differential Systemic Sclerosis Disease Severity
Kamini Kuchinad¹, Ji Soo Kim¹, Adrianne Woods¹, Gwen Leatherman¹, Laura Gutierrez², Maureen Mayes³, Robyn Domsic⁴, Paula Ramos⁵, Richard Silver⁵, John Varga⁶, Lesley Ann Saketkoo⁷, Suzanne Kafaja⁸, Victoria Shanmugam⁹, Jessica Gordon¹⁰, Lorinda Chung¹¹, Elana Bernstein¹², Pravitt Gourh¹³, Francesco Boin¹⁴, Daniel Kastner¹⁵, Scott Zeger¹⁶, Livia Casciola-Rosen¹, Fred Wigley¹ and Ami Shah¹⁷, ¹Department of Rheumatology, Johns Hopkins Medicine, Baltimore, MD, ²Johns Hopkins Medicine, Baltimore, MD, ³Division of Rheumatology, University of Texas McGovern Medical School, Houston, TX, ⁴University of Pittsburgh, Pittsburgh, PA, ⁵Medical University of South Carolina, Charleston, SC, ⁶University of Michigan, Ann Arbor, MI, ⁷University Medical Center - Comprehensive Pulmonary Hypertension Center and ILD Clinic Programs // New Orleans Scleroderma and Sarcoidosis Patient Care & Research Centeris, New Orleans, LA, ⁸UCLA Department of Medicine, Division of Rheumatology, Los Angeles, CA, ⁹Victoria Shanmugam, MD, Great Falls, VA, ¹⁰Hospital for Special Surgery, New York, NY, ¹¹Department of Medicine, Division of Immunology and Rheumatology, Stanford University School of Medicine, Woodside, CA, ¹²Columbia University, New York, NY, ¹³National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ¹⁴Cedars-Sinai Medical Center, Los Angeles, CA, ¹⁵National Human Genome Research Institute, Bethesda, MD, ¹⁶Johns Hopkins University, Baltimore, MD, ¹⁷Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Ellicott City, MD
Background/Purpose: Individuals with self-identified Black race have a higher incidence of systemic sclerosis (SSc), develop SSc at a younger age, and have a more severe…
Abstract Number: 0432 • ACR Convergence 2023
Predictors of Use, Survival and Safety of Tofacitinib Monotherapy vs. in Combination with CsDMARDs in Daily Clinical Practice
Rodolfo Perez-Alamino¹, Carolina Isnardi², Enrique Soriano³, Luciano Lo Giudice⁴, johana zacariaz hereter⁴, Gustavo Casado⁵, Victor Caputo⁵, Andrea Schmichowski⁵, Cecilia Romeo⁵, Estela Rivero⁵, Florencia Savy⁶, Mercedes García⁷, Olga Romano¹, Hernan Maldonado Ficco⁸ and Gustavo Citera², ¹Hospital Avellaneda, Tucuman, Argentina, ²IREP, Buenos Aires, Argentina, ³Rheumatology Section, Internal Medicine Services, Hospital Italiano de Buenos Aires, and University Institute Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁴Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁵Hospital Militar Central, Buenos Aires, Argentina, ⁶HIGA San Martin, La Plata, Argentina, ⁷Hospital Interzonal General de Agudos José de San Martín, La Plata, Argentina, ⁸Hospital San Antonio de Padua, Río Cuarto, Argentina
Background/Purpose: Different guidelines recommend the use of tofacitinib either in monotherapy or combined with methotrexate (combination therapy) in patients with rheumatoid arthritis (RA) with an…
Abstract Number: 0648 • ACR Convergence 2023
Incidence and Prevalence of Malnutrition and Its Impact on Mortality in the Multicentre Singapore Systemic Sclerosis Cohort
Bochao Jiang¹, Ennaliza Salazar², Seyed Ehsan Saffari³, Gim Gee Teng⁴, Xin Rong Lim⁵, Sue-Ann Ng², Amelia Santosa⁶, Cassandra Hong² and Andrea Hsiu Ling Low⁷, ¹Ministry of Health Holdings, Singapura, Singapore, ²Singapore General Hospital, Singapore, Singapore, ³Center for Quantitative Medicine, Duke-NUS Medical School, National University of Singapore, Singapore, Singapore, ⁴Alexandra Hospital, Department of Medicine, Division of Rheumatology, National University Health System, Singapore, Singapore, ⁵Tan Tock Seng Hospital, Singapore, Singapore, ⁶Division of Rheumatology, Department of Medicine, National University Hospital, National University Health System, Singapore, Singapore, ⁷Department of Rheumatology and Immunology, Singapore General Hospital, Singapore, Singapore
Background/Purpose: Gastrointestinal (GI) involvement is common in patients with systemic sclerosis (SSc), and may lead to malnutrition that adversely affects quality of life, morbidity and…
Abstract Number: 0548 • ACR Convergence 2023
Clinical and Interferon Biomarkers to Exclude Imminent Autoimmune Disease in ANA Positive Individuals
Md Yuzaiful Md Yusof¹, Sabih Ul-Hassan¹, Zoe Wigston¹, Antonios Psarras², Jack Arnold¹, Lucy Carter³, Paul Emery⁴ and Ed Vital¹, ¹University of Leeds, Leeds, United Kingdom, ²Oxford University, Oxford, United Kingdom, ³University of Leeds, Hartlepool, United Kingdom, ⁴Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
Background/Purpose: Many rheumatologists find it challenging to safely discharge "At-Risk" ANA-positive people at the first visit due to lack of cardinal signs and prediction tools.…
Abstract Number: 0566 • ACR Convergence 2023
Characterization of Disease Activity Using a Novel Physiologic Biomarker in Pediatric SLE
Sangeeta Sule, Olivia Lamanna, Kevin Jackson, Sun-Young Ahn, Tineer Ahmed and Julia Finkel, Children's National Hospital, Washington, DC
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex inflammatory disease involving many organ systems. To better understand and treat SLE, two phenotypes have been proposed.…
Abstract Number: 0402 • ACR Convergence 2023
Automated Detection and Quantification of Hand Joint Swelling in Rheumatoid Arthritis: Computer Vision, Deep Neural Network Models, and a Potential Biomarker for Disease Activity Monitoring
Marc Blanchard¹, Jules Maglione², Cinja Koller³, Patrick Hermann⁴, David Brüschweiler³, Arnd Kleyer⁵ and Thomas Hügle⁶, ¹Dept. of Rheumatology, University Hospital Lausanne (CHUV) and University Lausanne, Lausanne, Switzerland, ²EPFL, Lausanne, Switzerland, ³Lausanne University Hospital, Lausanne, Switzerland, ⁴ATREON SA, Lausanne, Switzerland, ⁵University Hospital Erlangen, Erlangen, Germany, ⁶Dept. of Rheumatology, University Hospital Lausanne (CHUV) and University of Lausanne, Lausanne, Switzerland
Background/Purpose: We have previously shown that automated detection and processing of dorsal finger fold patterns from hand photographs can be used as a digital biomarker…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].